KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Novavax (NVAX) EBIAT (2016 - 2025)

Novavax (NVAX) has 16 years of EBIAT data on record, last reported at $17.5 million in Q4 2025.

  • For Q4 2025, EBIAT rose 121.61% year-over-year to $17.5 million; the TTM value through Dec 2025 reached $440.3 million, up 334.82%, while the annual FY2025 figure was $440.3 million, 334.83% up from the prior year.
  • EBIAT reached $17.5 million in Q4 2025 per NVAX's latest filing, up from -$202.4 million in the prior quarter.
  • Across five years, EBIAT topped out at $518.6 million in Q1 2025 and bottomed at -$846.3 million in Q4 2021.
  • Average EBIAT over 5 years is -$134.7 million, with a median of -$158.1 million recorded in 2022.
  • Peak YoY movement for EBIAT: crashed 1910.83% in 2021, then soared 451.51% in 2025.
  • A 5-year view of EBIAT shows it stood at -$846.3 million in 2021, then surged by 78.46% to -$182.2 million in 2022, then rose by 2.12% to -$178.4 million in 2023, then skyrocketed by 54.59% to -$81.0 million in 2024, then soared by 121.61% to $17.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were $17.5 million in Q4 2025, -$202.4 million in Q3 2025, and $106.5 million in Q2 2025.